New Long-Acting shot for schizophrenia shows promise in small study
Disease control
Completed
This study tested a long-acting injectable form of risperidone (Risperdal Consta) in 31 people with schizophrenia or schizoaffective disorder who were already receiving home-care treatment. Participants switched from their usual antipsychotic medication to receive a shot every tw…
Phase: PHASE4 • Sponsor: Johnson & Johnson Taiwan Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC